Michael D. West, Ph.D. is co-CEO of BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, having served as CEO from 2007 to 2015. He is also CEO of BioTime subsidiary AgeX Therapeutics, focused on the emerging field of interventional gerontology. Prior to joining BioTime he served in a variety of roles, including Chairman, CEO and Chief Scientific Officer at Advanced Cell Technology, which, as Ocata Therapeutics, was acquired by Astellas Pharma of Japan in 2016 for $379 million.
In 1990 Dr. West founded Geron Corp. (Nasdaq: GERN) with backing from Kleiner, Perkins, Caufield & Byers and Venrock. For its scientific team he recruited Drs. Elizabeth Blackburn, Carol Greider and Jack Szostak, who collectively went on to win the Nobel Prize in Medicine, and for its clinical advisory board he recruited Nobel laureate Dr. James Watson as well as Prof. Leonard Hayflick and others. While at Geron he also created the research consortium with Prof. James Thomson that led to the first isolation of human embryonic stem cells.
Dr. West also serves on the Board of Directors of BioTime affiliate company Asterias Biotherapeutics (NYSE American: AST). He received a B.S. Degree from Rensselaer Polytechnic Institute in 1976, an M.S. in Biology from Andrews University in 1982, and a Ph.D. with a concentration on the biology of cellular aging from Baylor College of Medicine in 1989. The author of numerous articles in peer-reviewed scientific journals, he also penned The Immortal Cell: One Scientist's Quest to Solve the Mystery of Human Aging (DoubleDay, 2003). He has been interviewed by The New York Times, The Wall Street Journal, The Economist, CNBC, ABC’s “Meet the Press,” and elsewhere, and has testified before the U.S. Congress about the potential lifesaving benefits of regenerative medicine.